nozt3e
2023.01.31 13:20

目前,$輝瑞.US 的 P 藥和默沙東的 M 藥 (Molnupiravir) 正瓜分着全球新冠口服藥市場,而在國內,P 藥的主要競爭對手則是上市不久的 M 藥、真實生物的阿茲夫定以及在 1 月 29 日才獲批的先聲藥業 SIM0417 和君實生物 VV116。其中,虧損擴大的 $君實生物.HK 壓力猶大。

The copyright of this article belongs to the original author/organization.

The current content only represents the author's point of view, and has nothing to do with the position of LongPort. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by LongPort, please contact us.

Like